J&J lupus drug meets primary endpoint in Phase 2 study
Source: SeekingAlpha
2026-06-03 00:28:50 ET
More on Johnson & Johnson
- Why We Increased The Position In Johnson & Johnson
- Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
- Johnson & Johnson: A Dividend King, But Priced Appropriately, Big Conference Slate
- J&J seeks expanded use for drug after positive head and neck cancer study
- J&J study suggests earlier use of prostate cancer drug improves outcomes
Read the full article on Seeking Alpha
For further details see:
J&J lupus drug meets primary endpoint in Phase 2 study
Johnson & Johnson
NASDAQ: JNJ
JNJ Trading
0.28% G/L:
$224.075 Last:
2,615,594 Volume:
$222.45 Open:
JNJ Latest News
June 03, 2026 12:25:00 pm
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
June 03, 2026 12:04:00 am
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
June 03, 2026 12:03:00 am
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
June 02, 2026 02:50:00 pm
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
JNJ Stock Data
$577,845,337,264
2,385,202,151
0.01%
2802
N/A
Pharmaceuticals
Healthcare
US
New Brunswick
